Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylenetetrazol-induced seizures.
Animals
Anticonvulsants
/ chemistry
Class I Phosphatidylinositol 3-Kinases
/ antagonists & inhibitors
Coumarins
/ chemistry
Disease Models, Animal
Drug Evaluation, Preclinical
Epilepsy
/ chemically induced
Gene Expression Profiling
Gene Expression Regulation
/ drug effects
Humans
Molecular Docking Simulation
Pentylenetetrazole
/ toxicity
Proto-Oncogene Proteins c-akt
/ metabolism
Pyrroles
/ chemistry
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ metabolism
Zebrafish
Zebrafish Proteins
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 05 2019
27 05 2019
Historique:
received:
14
02
2019
accepted:
14
05
2019
entrez:
29
5
2019
pubmed:
28
5
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Pyrrolone-fused benzosuberene (PBS) compounds were semi-synthesized from α,β,γ-Himachalenes extracted from the essential oil of Cedrus deodara following amino-vinyl-bromide substituted benzosuberenes as intermediates. These PBSs compounds classified as an attractive source of therapeutics. The α-isoform of PI3K which is a pivotal modulator of PI3K/AKT/mTOR signaling pathway, responsible for neurological disorders like epilepsy, found as a potential target molecule against these 17 semi-synthesized PBS compounds using in silico ligand-based pharmacophore mapping and target screening. The compounds screened using binding affinities, ADMET properties, and toxicity that were accessed by in silico docking simulations and pharmacokinetics profiling. Ultimately two compounds viz., PBS-8 and PBS-9 were selected for further in vivo evaluation using a zebrafish (Danio rerio) model of pentylenetetrazol (PTZ)-induced clonic convulsions. Additionally, gene expression studies performed for the genes of the PI3K/AKT/mTOR pathway which further validated our results. In conclusion, these findings suggested that PBS-8 is a promising candidate that could bedeveloped as a potential antiepileptic.
Identifiants
pubmed: 31133639
doi: 10.1038/s41598-019-44264-6
pii: 10.1038/s41598-019-44264-6
pmc: PMC6536720
doi:
Substances chimiques
Anticonvulsants
0
Coumarins
0
Pyrroles
0
Zebrafish Proteins
0
benzosuberene
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
mTOR protein, zebrafish
EC 2.7.11.1
Pentylenetetrazole
WM5Z385K7T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7904Références
Comput Biol Chem. 2018 Apr;73:213-220
pubmed: 29510339
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Drug Discov Today Technol. 2013 Sep;10(3):e395-401
pubmed: 24050136
Oncogene. 2002 Sep 26;21(43):6587-97
pubmed: 12242656
Trends Pharmacol Sci. 2015 Feb;36(2):78-95
pubmed: 25543280
CNS Neurol Disord Drug Targets. 2016;15(8):945-955
pubmed: 27306063
J Huazhong Univ Sci Technolog Med Sci. 2012 Dec;32(6):856-860
pubmed: 23271286
Biomed Pharmacother. 2018 Jan;97:1501-1513
pubmed: 29793313
Science. 1987 Jul 10;237(4811):192-7
pubmed: 3037702
Nat Rev Drug Discov. 2009 Aug;8(8):627-44
pubmed: 19644473
Nat Genet. 1999 Jan;21(1):99-102
pubmed: 9916799
Dis Model Mech. 2012 Nov;5(6):773-84
pubmed: 22730455
Exp Ther Med. 2018 Jan;15(1):1136-1142
pubmed: 29399113
Brain Behav Immun. 2019 Jan;75:84-93
pubmed: 30243822
Neuropharmacology. 2018 Sep 15;140:107-120
pubmed: 30081001
J Med Chem. 1999 May 6;42(9):1481-500
pubmed: 10229619
J Biol Chem. 1994 Feb 18;269(7):5241-8
pubmed: 8106507
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
J Med Chem. 1990 Sep;33(9):2311-9
pubmed: 2202827
Exp Cell Res. 1999 Nov 25;253(1):239-54
pubmed: 10579926
Adv Cancer Res. 2005;94:29-86
pubmed: 16095999
Neuroscience. 2005;131(3):759-68
pubmed: 15730879
J Neuroimmunol. 2015 May 15;282:110-7
pubmed: 25903737
J Neurol Sci. 2013 Sep 15;332(1-2):4-15
pubmed: 23773767
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8
pubmed: 23726034
Dev Biol. 2018 Sep 1;441(1):95-103
pubmed: 29953879
Annu Rev Cell Dev Biol. 2001;17:615-75
pubmed: 11687500
Curr Opin Oncol. 2006 Jan;18(1):77-82
pubmed: 16357568
Protein Eng. 1995 Feb;8(2):127-34
pubmed: 7630882
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Divers. 2012 May;16(2):357-66
pubmed: 22584731
J Mol Neurosci. 2018 Jun;65(2):234-245
pubmed: 29858824
J Med Chem. 2009 Jan 22;52(2):369-78
pubmed: 19143566